title: Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
abstract: With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5-S-cysteinyl-dopa levels were significantly increased in patients with stages III (n = 38) and IV (n = 20) MM compared with patients with stages 0-II (n = 62) MM. In addition, in patients with stages III and IV MM, serum 5-S-cysteinyl-dopa levels of more than 15.0 nmol/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages III-IV), serum 5-S-cysteinyl-dopa levels exceeded the normal limit of 10.0 nmol/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5-S-cysteinyl-dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.
authors: Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.|Melanoma Center, Okayama University Hospital, Okayama, Japan.
authors: Hiroshi
authors: H
authors: Umemura
authors: Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.|Melanoma Center, Okayama University Hospital, Okayama, Japan.
authors: Osamu
authors: O
authors: Yamasaki
authors: Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.|Melanoma Center, Okayama University Hospital, Okayama, Japan.
authors: Tatsuya
authors: T
authors: Kaji
authors: Division of Dermatology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
authors: Masaki
authors: M
authors: Otsuka
authors: Department of Dermatology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
authors: Kenji
authors: K
authors: Asagoe
authors: Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
authors: Minoru
authors: M
authors: Takata
authors: Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.|Melanoma Center, Okayama University Hospital, Okayama, Japan.
authors: Keiji
authors: K
authors: Iwatsuki
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D003548:Cysteinyldopa / Q000097:blood*; D004295:Dihydroxyphenylalanine; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan / Q000453:epidemiology; D053208:Kaplan-Meier Estimate; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000401:mortality; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D003548:Cysteinyldopa; D004295:Dihydroxyphenylalanine; D007770:L-Lactate Dehydrogenase
keywords: 5-S-cysteinyl-dopa; biomarker; lactate dehydrogenase; malignant melanoma; serum 5-S-CD